CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy
- 12 March 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (6) , 950-962
Abstract
Growing evidence suggests that tumor-associated macrophages (TAM) promote cancer progression and therapeutic resistance by enhancing angiogenesis, matrix-remodeling, and immunosuppression. In this study, prostate cancer under androgen blockade therapy (ABT) was investigated, demonstrating that TAMs contribute to prostate cancer disease recurrence through paracrine signaling processes. ABT induced the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1) and other cytokines that recruit and modulate macrophages, causing a significant increase in TAM infiltration. Inhibitors of CSF1 signaling through its receptor, CSF1R, were tested in combination with ABT, demonstrating that blockade of TAM influx in this setting disrupts tumor promotion and sustains a more durable therapeutic response compared with ABT alone. Cancer Res; 75(6); 950–62. ©2015 AACR.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16BNature Medicine, 2012
- Targeting Tyrosine Kinases and Autophagy in Prostate CancerDiscover Oncology, 2010
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorProceedings of the National Academy of Sciences, 2010
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancerNature, 2010
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse modelsProceedings of the National Academy of Sciences, 2009
- Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic AxisCancer Research, 2008
- Modulating metastasis by a lymphangiogenic switch in prostate cancerInternational Journal of Cancer, 2007
- Alternative activation of macrophagesNature Reviews Immunology, 2003
- Inflammation and cancerNature, 2002
- The Hallmarks of CancerCell, 2000